ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Q&As

Q&As

©bleakstar/Shuttersstock.com

The 2015 recommendations for PsA treatment highlight the importance of managing comorbidities and a patient-centered treatment approach.

Spine (©Lightspring/Shutterstock.com)

Predictive modeling data can steer physicians toward making healthcare decisions that have positive outcomes for patients.

(©ksenvitaln/Shutterstock.com)

Q&A: Two experts discuss proposals for formal CVD risk calculators in RA and the need for long-term research to validate them.

Barbara Vilen, Ph.D.

In this Q&A, Rheumatology Network speaks with Dr. Barbara Vilen who is making strides in both basic and translational research that may lead to new therapeutic targets for lupus.

Stephen Katz M.D., Ph.D.

In this Q&A, Rheumatology Network speaks with Dr. Stephen Katz about the NIAMS Action Plan for Lupus Research.

Timothy B. Niewold, M.D

With the hope of wasting less time on medications doomed to fail, researchers are seeking biomarkers to predict a patient’s response to particular RA treatments.

Prem N. Ramkumar, M.D.

Prem N. Ramkumar, M.D., the author of a recent analysis on readmission rates in TJA, speaks with Rheumatology Network about why readmission rates matter.

Pages

Subscribe to Q&As on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.